Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent.
The aims of this study were to determine whether combining features of a western lifestyle in mice with trans fats in a high-fat diet, high-fructose corn syrup in the water, and interventions designed to promote sedentary behavior would cause the hepatic histopathological and metabolic abnormalities that characterize nonalcoholic steatohepatitis (NASH). Male C57BL/6 mice fed ad libitum high-fat chow containing trans fats (partially hydrogenated vegetable oil) and relevant amounts of a high-fructose corn syrup (HFCS) equivalent for 1-16 wk were compared with mice fed standard chow or mice with trans fats or HFCS omitted. Cage racks were removed from western diet mice to promote sedentary behavior. By 16 wk, trans fat-fed mice became obese and developed severe hepatic steatosis with associated necroinflammatory changes. Plasma alanine aminotransferase levels increased, as did liver TNF-alpha and procollagen mRNA, indicating an inflammatory and profibrogenic response to injury. Glucose intolerance and impaired fasting glucose developed within 2 and 4 wk, respectively. Plasma insulin, resistin, and leptin levels increased in a profile similar to that seen in patients with NASH. The individual components of this diet contributed to the phenotype independently; isocaloric replacement of trans fats with lard established that trans fats played a major role in promoting hepatic steatosis and injury, whereas inclusion of HFCS promoted food consumption, obesity, and impaired insulin sensitivity. Combining risk factors for the metabolic syndrome by feeding mice trans fats and HFCS induced histological features of NASH in the context of a metabolic profile similar to patients with this disease. Because dietary trans fats promoted liver steatosis and injury, their role in the epidemic of NASH needs further evaluation.
Tetri
Laura H
LH
Department of Internal Medicine, Saint Louis University, MO, USA.
Basaranoglu
Metin
M
Brunt
Elizabeth M
EM
Yerian
Lisa M
LM
Neuschwander-Tetri
Brent A
BA
D000818:Animals; D004032:Diet; D004041:Dietary Fats / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005234:Fatty Liver / Q000139:chemically induced* / Q000473:pathology*; D005632:Fructose / Q000737:chemistry*; D007249:Inflammation / Q000139:chemically induced* / Q000473:pathology; D008099:Liver / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009336:Necrosis / Q000139:chemically induced* / Q000473:pathology; D013549:Sweetening Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D044242:Trans Fatty Acids / Q000008:administration & dosage / Q000633:toxicity*; D003313:Zea mays
D004041:Dietary Fats; D013549:Sweetening Agents; D044242:Trans Fatty Acids; D005632:Fructose
Diabetes. 2004 Dec;53(12):3274-85
15561960
J Clin Invest. 1993 Sep;92(3):1126-34
8397219
Radiology. 1989 May;171(2):557-63
2704824
Obes Res. 2005 Jul;13(7):1146-56
16076983
Blood Press. 2004;13(6):355-61
15771220
Circulation. 2007 Jul 31;116(5):480-8
17646581
JAMA. 1999 Nov 3;282(17):1659-64
10553793
Acta Biol Med Ger. 1981;40(12):1699-1705
7345825
Am J Physiol Endocrinol Metab. 2004 May;286(5):E828-33
14722026
JAMA. 2003 Apr 9;289(14):1785-91
12684356
Ann Intern Med. 2000 Jul 18;133(2):92-103
10896648
Gut. 2008 May;57(5):649-54
18276725
Am J Physiol Gastrointest Liver Physiol. 2008 Mar;294(3):G619-26
18174272
Metabolism. 2005 Feb;54(2):240-6
15789505
Mol Cell Biol. 2006 Feb;26(3):1063-76
16428458
N Engl J Med. 2006 Apr 13;354(15):1650-2
16611965
Semin Liver Dis. 2001;21(1):89-104
11296700
Int J Exp Pathol. 2006 Feb;87(1):1-16
16436109
Gut. 2008 May;57(5):568-70
18408097
Hepatology. 2005 Sep;42(3):641-9
16116629
J Mol Endocrinol. 2006 Jun;36(3):485-501
16720718
N Engl J Med. 2006 Apr 13;354(15):1601-13
16611951
BMJ. 2004 May 22;328(7450):1237
15107313
Obesity (Silver Spring). 2006 Jul;14(7):1118-23
16899792
Atheroscler Suppl. 2006 May;7(2):47-52
16713385
Diabetes. 2005 Jul;54(7):1907-13
15983189
J Nutr. 2000 Jun;130(6):1531-5
10827205
Biochem J. 1998 Jan 1;329 ( Pt 1):17-35
9405271
J Clin Endocrinol Metab. 2004 Jun;89(6):2963-72
15181085
Cell Metab. 2007 Jul;6(1):69-78
17618857
Atheroscler Suppl. 2006 May;7(2):37-9
16713388
Diabetes. 2000 May;49(5):749-58
10905483
J Hepatol. 2004 Jan;40(1):47-51
14672613
Hepatology. 2003 Jul;38(1):123-32
12829994
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):644-9
14715643
J Appl Physiol (1985). 2003 Jun;94(6):2127-34
12547845
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
10902785
Am J Clin Nutr. 2002 Nov;76(5):911-22
12399260
Endocrinology. 2004 Jul;145(7):3258-64
15059949
Exp Mol Pathol. 2004 Dec;77(3):168-75
15507232
J Am Diet Assoc. 2008 Feb;108(2):367-70
18237584